The Chinese subsidiaries of Johnson & Johnson said on Friday morning they will continue doing business in China after an anti-trust ruling on Thursday.

While being "disappointed with the ruling", Johnson & Johnson Medical China Ltd said in a written response to China Daily that the company is pleased to have "put this matter” behind them and will continue to provide high-quality products and services to healthcare institutions and patients in China.

Shanghai High People's Court ordered the US giant's Chinese subsidiaries to pay 530,000 yuan ($86,456) in compensation for price fixing to a former dealer, Rainbow Medical.

The court said the medical care giant adopted a monopolistic practice by setting a price floor for its Chinese dealer in 2008.